Author

Chinyu Su 1

1 Pfizer Inc,Collegeville,United States

BASELINE ALBUMIN LEVEL IS NOT A SIGNIFICANT PREDICTOR OF TOFACITINIB EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS: RESULTS OF MULTIVARIATE EXPOSURE-RESPONSE ANALYSIS

Gary R. Lichtenstein, Andrew Tinsley, Xavier Roblin, Tadakazu Hisamatsu, Camille Vong, Shinichi Tsuchiwata, Konstantinos Tsilkos, Haiying Zhang, Arnab Mukherjee, Chinyu Su, David T. Rubin

ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE ULCERATIVE COLITIS PROGRAMME FOR TOFACITINIB

Bruce E. Sands, Millie D. Long, Leonard Baidoo, Walter Reinisch, Julian Panés, Chudy I. Nduaka, Arif Soonasra, Ronald D. Pedersen, Nervin Lawendy, Gary Chan, Gary S. Friedman, Chinyu Su

MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY

Jean-Frederic Colombel, Walter Reinisch, Mark T. Osterman, Andrew J. Thorpe, Chudy I. Nduaka, Haiying Zhang, Nervin Lawendy, Gary S. Friedman, Chinyu Su

Incidence of venous thromboembolic events in patients with ulcerative colitis treated with tofacitinib in the ulcerative colitis clinical development programme

William Sandborn, Julian Panés, Bruce E. Sands, Walter Reinisch, Chinyu Su, Nervin Lawendy, Nana Koram, Haiyun Fan, Thomas V Jones, Irene Modesto, Daniel Quirk, Silvio Danese

PREGNANCY OUTCOMES IN THE TOFACITINIB ULCERATIVE COLITIS OCTAVE STUDIES

Uma Mahadevan, Daniel C. Baumgart, Marla C. Dubinsky, Nervin Lawendy, Gary S. Friedman, Gauree G. Konijeti, Hans Peter Gröchenig, Thomas V Jones, Amy Marren, Andrew J. Thorpe, Chudy I. Nduaka, Chinyu Su

Faecal calprotectin levels, C-reactive protein levels and partial Mayo score as early predictors of clinical and endoscopic outcomes in adult patients with moderately to severely active ulcerative colitis treated with tofacitinib in a Phase 2 study

Marla C. Dubinsky, David P. Hudesman, nicole kulisek, Leonardo Salese, Jerome Paulissen, Chinyu Su, Fernando Jose Magro Dias

INTEGRATED SAFETY ANALYSES OF TOFACITINIB IN ULCERATIVE COLITIS CLINICAL TRIALS

William Sandborn, Julian Panés, Geert R. D'Haens, Bruce E. Sands, Chinyu Su, Michele Moscariello, Thomas V Jones, Ron Pedersen, Gary S. Friedman, Nervin Lawendy, Gary Chan

TOFACITINIB HAS INDUCTION EFFICACY IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS, REGARDLESS OF PRIOR TNF INHIBITOR THERAPY

Geert R. D'Haens, Bruce E. Sands, William Sandborn, Toshifumi Hibi, Chinyu Su, Wojciech Niezychowski, Subrata Ghosh, Haiying Zhang, Dahong Yu, Deborah A. Woodworth, Paul Healey, Amy Marren, Julian Panés

TOFACITINIB FOR MAINTENANCE THERAPY IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS IN THE PHASE 3 OCTAVE SUSTAIN TRIAL: RESULTS BY LOCAL AND CENTRAL ENDOSCOPIC ASSESSMENTS

Brian G. Feagan, Severine Vermeire, William Sandborn, Walter Reinisch, Julian Panés, Dino Tarabar, Chinyu Su, Wojciech Niezychowski, Haiying Zhang, Gary S. Friedman, Deborah A. Woodworth, Bruce E. Sands

Impact of baseline corticosteroid therapy on tofacitinib induction efficacy and infection risk in patients with ulcerative colitis: data from global clinical trials

Gary R. Lichtenstein, Benjamin L. Cohen, Leonardo Salese, Arif Soonasra, Irene Modesto, Wenjin Wang, Deborah.A Woodworth, Gary Chan, Daniel Quirk, Chinyu Su, Laurent Peyrin‐Biroulet

Item 1 - 10 / 18
1
2